Table 1.
Demographic Characteristics and Outcomes of Patients With mrCDI Who Received a FDX-CH Regimen*
| Age, Years/Sex | No. of CDI Episodes | Prior Regimens | Additional Antimicrobial Exposure After the Last Prior Regimen | Longest SFI for Non-FDX-CH Course, Days (Antibiotic) | SFI Post FDX-CH, Days | Recurrence After FDX-CH | Additional Antimicrobial Exposure After FDX-CH Regimens | |
|---|---|---|---|---|---|---|---|---|
| Patient 1† | 67/M | 4 | M, M, VT, VT, VT, VT | None | 18 (VT) | 857 | No | None |
| Patient 2† | 83/F | 5 | V,V,V,V,VT,VT,VT | None | 20 (VT) | 92 | Yes | Yes |
| Patient 3† | 32/F | 8 | M,M,VT,VT,V + RC,V + RC,VT + IVIG,VT | None | 42 (RC) | 839 | No | None |
| Patient 4 | 68/F | 4 | M,M,VT | None | 64 (VT) | 19 | Yes | None |
| Patient 5 | 46/F | 10 | M, V, V, VT, V + FMT, V, RC, VT, VT, VT | None | 102 (V) | 34 | Yes | None |
| Patient 6 | 90/F | 3 | V,VT,VT | None | 82 (V) | 689 | No | None |
| Patient 7 | 79/M | 6 | U,U,U,VT,VT,VT | None | 90 (VT) | 419 | No | None |
| Patient 8 | 70/F | 4 | M + V,V,VT,VT | None | 49 (VT) | 137 | No | None |
| Mean ± SD | 66.9 ± 19 | 5.5 ± 2 | Median (IQR) | 56.5 (48) | 278 (649)‡ |
Abbreviations: CDI, Clostridium difficile infection; FDX, standard fidaxomicin treatment regimen; FDX-CH, fidaxomicin chaser; FDX-TP, fidaxomicin taper; FMT, fecal microbiota transplantation; IQR, interquartile range; IVIG, intravenous immunoglobulin; M, metronidazole; mrCDI, multiple recurrent CDI; RC, rifaximin chaser; SD, standard deviation; SFI, symptom-free interval; U, unknown; V, standard vancomycin treatment course; VT, vancomycin taper.
* The SFI after the most effective prior treatment is compared to the SFI after FDX-CH.
† Patients 1–3 were previously reported [16].
‡ P = .066 compared with non-FDX-CH SFI, Mann–Whitney U test.